DESCRIPTION

Regenerative Medicine is the process of creating living, functional tissues to repair or replace tissue or organ function lost due to age, disease, damage, or congenital defects. This field holds the promise of regenerating damaged tissues and organs in the body by stimulating previously irreparable organs to heal themselves. Regenerative medicine also empowers scientists to grow tissues and organs in the laboratory and safely implant them when the body cannot heal itself. Importantly, regenerative medicine has the potential to solve the problem of the shortage of organs available through donation compared to the number of patients that require life-saving organ transplantation

• The rapid development of transplant medicine along with the aging of the baby boomer generation has caused an increased demand for tissues and organs far exceeding the available donor organs.

• Approximately 500,000 Americans benefit from a transplant each year.

• As of August 2010, there were approximately 108,000 people on the waiting list for donor organs. Many of these individuals will die before a suitable organ can be found.

• Tissue-engineered skin has been used for skin replacement, temporary wound cover for burns, and treatment for diabetic leg and foot ulcers.

• Tissue-engineered bladder, derived from a patient’s own cells, can be grown outside the body and successfully transplanted.

• A material developed from the small intestines of pigs is increasingly used by surgeons to restore damaged tissues and support the body’s own healing processes. Physicians rely on the material, called small intestinal submucosa (SIS), for everything from reconstructing ligaments to treating incontinence. Today, SIS is most commonly used to help the body close hard-to-heal wounds such as second-degree burns, chronic pressure ulcers, diabetic skin ulcers, and deep skin lacerations.

• Tissue-engineered products are used to induce bone and connective tissue growth, guide long bone regeneration, and replace damaged knee cartilage.

• Tissue-engineered vascular grafts for heart bypass surgery and cardiovascular disease treatment are at the pre-clinical trial stage.

• Stem and precursor cells are available from a wide variety of sources (e.g., embryos, gestational and adult tissues, and reprogrammed differentiated cells). This increases the sophistication, variety and utility of engineered tissues. Animal and small pilot human studies are currently paving the way for large scale clinical trials to treat many intractable diseases